# Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation

> **NCT03989089** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Malaya** · enrollment: 44 (actual)

## Conditions studied

- HER2-Negative Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03989089
- **Lead sponsor:** University of Malaya
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-03
- **Primary completion:** 2025-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-12-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03989089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03989089, "Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03989089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*